Galena Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 91   

Articles published

GALE 1.95 +0.10 (5.41%)
price chart
Why Galena Biopharma, Inc. Stock Crashed By 52% in 2014
The overall market may be on pace to deliver solid gains for investors in 2014, but shareholders in Galena Biopharma (NASDAQ: GALE ) can do nothing but shake their head in disappointment with their stock down 52% for the year.
Related articles »  
Why Galena Biopharma Inc. Stock Sank 13% in November
What: Shares of Galena Biopharma (NASDAQ: GALE ) , a biopharmaceutical company focused on developing immunotherapies to treat cancer, sank 13% in November, based on data from S&P Capital IQ, following a weak earnings report and a questionable ...
Related articles »  
Galena Biopharma, Inc. Price Target Update
Galena Biopharma, Inc. (NASDAQ:GALE): 6 Analyst have given the stock of Galena Biopharma, Inc. (NASDAQ:GALE) a near short term price target of $5.83.
Galena Biopharma (GALE) to Release Quarterly Earnings on Thursday  Mideast Time
Healthcare Sector Movers: Tenet Healthcare Corp. (THC), Biocept, Inc. (BIOC ...  WallStreet Scope
Could Galena Biopharma, Inc. Be Running Out of Money?
Today, we're going to take a closer look at small-cap biopharmaceutical company Galena Biopharma (NASDAQ: GALE ) to get a better bead on what its current cash situation looks like, to determine whether or not it could be running out of money, and to ...
Galena Biopharma Inc. (GALE) is Trading Lower on Unusual Volume for ...
Galena Biopharma Inc. ($GALE) experienced unusually high volume on Feb. 19, as the stock [gained/lost] 5.68% to a closing price of $1.86.
Zacks Long Term Rating Update on Galena Biopharma Inc
As much as 6 analysts have advised buy on Galena Biopharma Inc (NASDAQ:GALE) with an average broker rating of 2.17. Research Analysts at Zacks has the counter a rating of 3, which implies that the firms recommendation is Neutral on the company.
Galena Biopharma Provides 2015 Outlook
PORTLAND, Ore., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full ...
Galena Biopharma (GALE) Guides FY15 Below Consensus Expectations  StreetInsider.com (subscription)
Galena Biopharma Enrolls 700th Patient in NeuVax(TM) (nelipepimut-S) Phase ...
PORTLAND, Ore., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full ...
Brokerage Firm Rating Disclosure Update on Galena Biopharma Inc  Wall Street Pulse
Galena Biopharma Hires Joseph Lasaga as Vice President, Business ...
PORTLAND, Ore., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full ...
Company Shares of Galena Biopharma Inc Rally 9.52%
Shares of Galena Biopharma Inc (NASDAQ:GALE) rose by 9.52% in the past week and 10.84% for the last 4 weeks. In the past week, the counter has outperformed the S&P 500 by 8.83% and the outperformance increases to 7.77% for the last 4 weeks.
Mid-Day Changers: Galena Biopharma, Inc. (GALE), Xencor, Inc. (XNCR ...  WallStreet Scope